Tumor-targeted chemotherapy has the potential to eliminate cancers by ensuring that anticancer drug delivery is precise and directed specifically at tumor sites. We have developed a nanomedicine platform that utilizes a human serum albumin complex as an ideal nanocarrier for encapsulating drugs. This innovative approach allows for the formulation of anticancer drugs without the use of toxic organic solvents. Furthermore, it preferentially targets and delivers these toxic drugs to tumor tissue while sparing normal tissues. Currently, our tumor-targeted chemotherapy using paclitaxel is in the clinical trial stage, showcasing the promise of our tumor-targeting nanomedicine platform.
The preparation methods for targeting-enhanced anticancer nanoparticles are crucial for developing effective anticancer drug delivery systems within a nanomedicine platform, particularly for tumor-targeted chemotherapy.